Clerkenwell Health, a London, UK-based clinical psychedelics startup, raised £2.1M in Seed funding.
Backers included Lionheart Ventures, Convergence Partners, and Exceptional Ventures.
The company intends to use the funds to support the operations of its clinical trials facility, Europe’s first commercial facility dedicated to psychedelic assisted therapies, opening this Autumn.
Led by CEO Tom McDonald, Clerkenwell Health is a clinical research organisation focused on supporting clients with the design and delivery of psychedelic-assisted therapy trials. They provide psychedelic research at scale through commercial centres of excellence which allow organisations to run clinical trials, co-develop drugs and be at the forefront of clinical innovation. They offer companies clinical trial support: scientific advisory, trial design, regulatory approvals, provision of suitable trial sites, and the monitoring and management of trials.
The company is supporting North American drug developers entering the UK. Toronto-based life sciences company Psyence (listed on the Canadian Securities Exchange (CSE: PSYG) and quoted on the OTCQB (OTCQB: PSYGF), has received approval from the MHRA to kick off the first trials at Clerkenwell’s London site. The clinical trial will assess the efficacy and safety of psilocybin-assisted psychotherapy versus psychotherapy alone for the treatment of adjustment disorder due to an incurable cancer diagnosis.
FinSMEs
10/10/2022